Methods for Treating Multiple Myeloma
AssigneeCelgene Corporation
InventorChih-Chao Hsu
Life of this patent
Estimating the term…
Abstract
Provided herein are methods of treating multiple myeloma, including multiple myeloma that is resistant to at least one therapeutic agent, comprising administering to a subject with multiple myeloma an inhibitor of Ubiquitin-Like with PHD and Ring Finger Domains 1 (UHRF1).
Claims44
A method of treating multiple myeloma, comprising administering to a subject with multiple myeloma a therapeutically effective amount of an inhibitor of Ubiquitin-Like with PHD and Ring Finger Domains 1 (UHRF1), wherein the multiple myeloma is resistant to at least one therapeutic agent.
A method of treating multiple myeloma, comprising administering to a subject with multiple myeloma a therapeutically effective amount of an inhibitor of Ubiquitin-Like with PHD and Ring Finger Domains 1 (UHRF1) and at least one additional therapeutic agent.
The method of any one of the preceding claims, wherein the inhibitor of UHRF1 is not an IMiDR.
The method of any one of the preceding claims, wherein the inhibitor of UHRF1 is a direct inhibitor of UHRF1.
The method of any one of the preceding claims, wherein the multiple myeloma cells express a UHRF1 transcript or protein.
A method of selecting a subject with multiple myeloma for treatment with a UHRF1 inhibitor, comprising determining the level of UHRF1 in a sample obtained from the subject, wherein if the level of UHRF1 in the sample is above a reference level, the subject is selected for treatment with a UHRF1 inhibitor.
A method of predicting whether a subject with multiple myeloma will benefit from treatment with a UHRF1 inhibitor, comprising determining whether the subject has a level of UHRF1 above a reference level.
A method of treating multiple myeloma, comprising administering to a subject with multiple myeloma a therapeutically effective amount of an inhibitor of Ubiquitin-Like with PHD and Ring Finger Domains 1 (UHRF1) and at least one additional therapeutic agent.
Dependencies are inferred from the claim text.